Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

ABSTRACT: This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

DISEASE(S): Adenocarcinoma,Sarcoma, Ewing,Colorectal Adenocarcinoma,Chondrosarcoma,Gastric Adenocarcinoma,Pancreatic Adenocarcinoma,Sarcoma,Colorectal Cancer,Mesothelioma,Malignant Pleural Mesothelioma,Colon Cancer,Mesothelioma, Malignant,Ewing Sarcoma,Solid Tumors

PROVIDER: 2287581 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR